Novo Nordisk Mexico and the Salvador Zubirán Institute signed a major agreement to develop clinical studies in cardiometabolic and rare diseases, aiming to boost Mexico's scientific presence.
In a move to elevate Mexico’s position on the global scientific stage, Danish pharmaceutical company Novo Nordisk Mexico has signed a strategic collaboration agreement with the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ). The partnership aims to conduct clinical studies in key therapeutic areas, including cardiometabolic conditions and low-prevalence diseases, according to a statement released by the company . . .
